ReviewWorld journal of hepatology2015
Treatment of hepatocellular carcinoma: Steps forward but still a long way to go.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance.Molecular medicine reports · 2017Pooled it
- Hepatocellular Carcinoma: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study.BMC surgery · 2023Article
- Article
- Role of preoperative prediction of microvascular invasion in hepatocellular carcinoma based on the texture of FDG PET image: A comparison of quantitative metabolic parameters and MRI.Frontiers in physiology · 2022Article
- Radiomics analysis of [European journal of nuclear medicine and molecular imaging · 2021Article
- Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.International journal of molecular sciences · 2021Review
- Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Discovery of SIRT7 Inhibitor as New Therapeutic Options Against Liver Cancer.Frontiers in cell and developmental biology · 2021Article
- Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells.Frontiers in pharmacology · 2021Article
- Corosolic Acid Inhibits Cancer Progress Through Inactivating YAP in Hepatocellular Carcinoma.Oncology research · 2020Article
- Downregulation of lncRNA DANCR promotes osteogenic differentiation of periodontal ligament stem cells.BMC developmental biology · 2020Article
- Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC.Journal for immunotherapy of cancer · 2019Article
- Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.World journal of hepatology · 2019Review
- Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.Journal of gastrointestinal cancer · 2018Review
- Preoperative prediction of microvascular invasion of hepatocellular carcinoma usingEuropean journal of nuclear medicine and molecular imaging · 2018Article
- Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization.World journal of gastroenterology · 2018Article
- CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents.Frontiers in pharmacology · 2018Article
- Women receive more inpatient resections and ablations for hepatocellular carcinoma than men.World journal of hepatology · 2017Article
- Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third cause of tumor associated deaths worldwide. HCC incidence rates are increasing in many parts of the world including developing and developed countries. Potentially curative treatments for HCC are resection and liver transplantation, but these are only suitable for patients with small tumors, meeting strict pre-defined criteria, or well-compensated liver disease. Early diagnosis of HCC can be achieved by surveillance of at-risk populations. For patients with non-resectable disease treatments modalities include loco-ablative and systemic therapies. In this review we focus on treatment options in HCC and their allocation. Although significant research is in progress, to this date, the results are unsatisfactory with limited long-term survival. In the fight against this deadly disease, there is still a long way to go.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.